Endocrine Abstracts

The most effective conventional treatment for differentiated thyroid cancer (DTC) still remains total thyroidectomy with subsequent adjuvant therapy with radioiodine ablation (RAI). In case of unsuccessful RAI treatment, an alternative method is the tyrosine kinase inhibitor therapy. However, its usage is related to many side effects and is not well tolerated by patients. Despite the great progress in the clinical management of patients with DTC, the lack of alternative therapies is remarkable. Since oxidative stress has been implicated as DTC risk factor, the determination of oxidative stress-related proteins may be useful in DTC clinical management, especially in angioinvasion diagnosis. The oxidative stress-related pathways profiling in DTC development analysis will enable a better understanding of the DTC progression simultaneously enabling new medical targets discovery. In this case, we analyzed the level of oxidative stress-related proteins, such as total oxidative stress capacity (TOC), total antioxidant capacity (TAC), sirtuin 1 (SIRT1), sirtuin 3 (SIRT3) and DNA oxidative stress damage products to determine their role in DTC angioinvasion processes and designate potential properties as targeted therapy. For this study 80 patients diagnosed with different stages of DTC after total thyroidectomy were enrolled. All patients were diagnosed as having papillary DTC based on laboratory tests and ultrasound imaging, and confirmed by fine needle aspiration biopsy, followed by histopathological examination. The study group consisted of DTC patients with angioinvasion and for the reference group DTC patients without angioinvasion were enrolled. Considering the received results, TAC, DNA oxidative stress damage products, SIRT1 and SIRT3 measurements have been implicated to DTC angioinvasion (P=0.04; P<0.001; P<0.05; P=0.01). Moreover, our study revealed that SIRT1 and DNA/RNA oxidative stress damage products are useful in detection of DTC angioinvasion, and thus could be considered as a marker supporting additional indication for RAI therapy (AUC=0.7; AUC=0.71; all P<0.05 respectively).